-
Je něco špatně v tomto záznamu ?
Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
Š. Kutílek, I. Plášilová, S. Skálová, M. Bayer, E. Ondrušová
Jazyk angličtina Země Česko
Typ dokumentu kazuistiky, časopisecké články
Digitální knihovna NLK
Zdroj
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2012-06-01
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- aplikace orální MeSH
- bisfosfonáty terapeutické užití MeSH
- dítě MeSH
- inhibitory kostní resorpce * terapeutické užití MeSH
- kostní denzita MeSH
- kyselina ibandronová * terapeutické užití MeSH
- lidé MeSH
- mladiství MeSH
- osteogenesis imperfecta * farmakoterapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
INTRODUCTION: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. CASE REPORT: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. CONCLUSION: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.
Department of Pediatrics Klatovy Hospital Klatovy Czech Republic
Department of Pediatrics Pardubice Hospital Pardubice Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21029377
- 003
- CZ-PrNML
- 005
- 20211206150444.0
- 007
- ta
- 008
- 211206s2021 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/18059694.2021.32 $2 doi
- 035 __
- $a (PubMed)34779386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Kutílek, Štěpán, $u Department of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic. kutilek@nemkt.cz $u Department of Pediatrics, Klatovy Hospital, Klatovy, Czech Republic. kutilek@nemkt.cz $u Department of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic. kutilek@nemkt.cz $d 1957- $7 xx0002376
- 245 10
- $a Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta / $c Š. Kutílek, I. Plášilová, S. Skálová, M. Bayer, E. Ondrušová
- 520 9_
- $a INTRODUCTION: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. CASE REPORT: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. CONCLUSION: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a kostní denzita $7 D015519
- 650 12
- $a inhibitory kostní resorpce $x terapeutické užití $7 D050071
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a bisfosfonáty $x terapeutické užití $7 D004164
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kyselina ibandronová $x terapeutické užití $7 D000077557
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a osteogenesis imperfecta $x farmakoterapie $7 D010013
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Plášilová, Ivana $u Department of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Department of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic $7 xx0171293
- 700 1_
- $a Skálová, Sylva, $u Department of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic $d 1964- $7 xx0105263
- 700 1_
- $a Bayer, Milan, $u Department of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Department of Pediatrics, 3rd Faculty of Medicine and University Hospital Královské Vinohrady, Charles University in Prague, Czech Republic $d 1956- $7 xx0002379
- 700 1_
- $a Ondrušová, Erika $u Department of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic $7 xx0099532
- 773 0_
- $w MED00010947 $t Acta Medica (Hradec Kralove) $x 1805-9694 $g Roč. 64, č. 3 (2021), s. 187-192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34779386 $y Pubmed
- 910 __
- $a ABA008 $b A 3077 $c 1072 $y p $z 0
- 990 __
- $a 20211206 $b ABA008
- 991 __
- $a 20211206135943 $b ABA008
- 999 __
- $a ok $b bmc $g 1731377 $s 1149930
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 64 $c 3 $d 187-192 $e 20211111 $i 1805-9694 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
- LZP __
- $b NLK138 $a Pubmed-20211206
